Company CVAbout Kilitch Drugs (India) Ltd 
Kilitch Drugs (India) Ltd
Micro Cap
Pharmaceuticals & Drugs
Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
Company Coordinates
Company Details
C-301/2 MIDC TTC Indl Area, Pawane Village Thane Maharashtra : 400705
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 16.08 Cr
Number of Shares
1.61 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
22-Jul-2023
1.61
16.08
500000
10
Conversion of Warrants
24-Jan-2022
1.61
16.08
500000
10
Issued under ESOP Scheme
13-Oct-2021
1.56
15.58
20305
10
Issued under ESOP Scheme
30-Apr-2021
1.56
15.56
67470
10
Issued under ESOP Scheme
25-May-2020
1.55
15.48
44883
10
Issued under ESOP Scheme
06-Sep-2019
1.54
15.43
16709
10
Issued under ESOP Scheme
22-Aug-2019
1.54
15.43
16709
10
Issued under ESOP Scheme
03-May-2019
1.54
15.42
62239
10
ESOP
29-Mar-2018
1.32
13.73
500000
10
Conversion of Warrants
14-Feb-2011
1.32
13.23
15750
10
ESOP
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 1 FIIs (0.0%)
Promoter with highest holding
Kilitch Company (pharma) Limited (41.22%)
Highest Public shareholder
Dipak Kanayalal Shah (3.11%)
Individual Investors Holdings
25.74%
Board of Directors
Management
Designation
Remuneration
Mukund P Mehta
Managing Director
60.0 lacs
Bhavin M Mehta
Whole-time Director
84.0 lacs
Hemang Engineer
Independent Director
25.0 k
Mira Bhavin Mehta
Whole-time Director
24.0 lacs
Murti Vasudev Krishna
Independent Director
30.0 k
Venkita Subramanian Rajan
Independent Director
5.0 k
Pushpa Nyoupane
Company Sec. & Compli. Officer
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Other Operating Revenues
0.69
1.36%
Other Operating Revenues
Other Operating Revenues
Stock DNARevenue and Profits:
Net Sales:
56 Cr
(Quarterly Results - Dec 2024)
Net Profit:
6 Cr
Pharmaceuticals & Drugs
INR 547 Cr (Micro Cap)
28.00
33
0.00%
-0.14
8.69%
2.93
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
